Drug profile

The FDA adverse-event record for Unspecified Midazolam

15 FDA reports name Unspecified Midazolam, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2131 of 2,679
by report volume (all drugs)
15
adverse-event reports
26.7%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Unspecified Midazolam ranks #2072 of 2679 by total reports (15). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2072
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Unspecified Midazolam has 15 reports now versus 12 in that prior snapshot: 3 more (25.0%).

Report change
+3
Death-coded reports
+1
Death-coded share
+1.7 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Unspecified Midazolam changes

Signature read: Unspecified Midazolam's 26.7% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
4
Deaths Reported
26.7%
Death-coded share of reports

Active Ingredients

Unspecified Midazolam

Administration Routes

UnknownIntravenousIntramuscularSubcutaneousOral

Species Affected

Dog 11
Cat 4

Most Affected Breeds

Retriever - Golden 3
Cat (other) 2
Domestic Shorthair 1
Retriever (unspecified) 1
Terrier - Boston 1
Spitz - American Eskimo Dog 1
Bulldog - French 1
Terrier (unspecified) 1
Terrier - Bull - American Pit 1
Domestic Longhair 1

Most Reported Reactions

Intentional misuse 6
Seizure NOS 6
Twitching 4
Bumping into walls 4
Disorientation 4
Death by euthanasia 3
Anorexia 3
Fever 2
Facial swelling (see also Skin) 2
Lack of efficacy - NOS 2
Overdose 2
Accidental exposure 2

Outcome Breakdown

Ongoing
5 (33.3%)
Recovered/Normal
4 (26.7%)
Outcome Unknown
2 (13.3%)
Euthanized
2 (13.3%)
Died
2 (13.3%)

Unspecified Midazolam: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Unspecified Midazolam (#2131 of 2,679 by report volume); death-coded 26.7%. PlainBreed drug row · death-coded share stamp 26.7% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →